Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake

By Yahoo! Finance   |   2 weeks ago
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) faces concerns about patient conversion to new treatments, affecting operating margins. RBC Capital lowered the price target to $420 but believes the cystic fibrosis franchise remains strong. The company may need better execution to justify its valuation.

Read More

Did you find this insightful?